The Speculative-Grade Composite Spread Narrows To 532 Basis Points Feb 13

  • ID: 2405006
  • February 2013
  • Standard & Poors
1 of 2

NEW YORK (Standard & Poor's) Feb. 11, 2013--Standard & Poor's investment-grade composite spread tightened by 1 basis point (bp) to 181 bps last Friday, and the speculative-grade composite spread contracted by 1 bp to 532 bps. By rating, the 'AA', 'A', 'BBB', and 'BB' spreads remained flat at 122 bps, 151 bps, 212 bps, and 363 bps, respectively. The 'B' spread narrowed by 5 bps to 552 bps and the 'CCC' spread widened by 8 bps to 884 bps. By industry, banks, industrials, and utilities remained flat at 214 bps, 248 bps, and 182 bps, respectively. Telecommunications widened by 1 bp to 281 bps and financial institutions tightened by 1 bp to 230 bps. The investment-grade composite spread is lower...

Companies mentioned in this report are:

Action: General Comment

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.